Mizuho Securities analyst Difei Yang maintained a Buy rating on Viveve Medical Inc (NASDAQ: VIVE) today and set a price target of $4. The company’s shares opened today at $2.54, close to its 52-week low of $1.60.
Yang noted:
“We don’t expect these payments to be material at this point and we continue to see execution on revenue ramp as key for the company. We like the technology, favorable demographics, potential to address the SUI market (Stress Urinary Incontinence) and attractive valuation. We maintain our Buy rating.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 20.3% and a 53.2% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.
Currently, the analyst consensus on Viveve Medical Inc is Strong Buy and the average price target is $7.25, representing a 185.4% upside.
In a report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $9 price target.
See today’s analyst top recommended stocks >>
Based on Viveve Medical Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $12.67 million. In comparison, last year the company had a GAAP net loss of $6.7 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Viveve Medical, Inc. engages in the provision of health products. Its activities include development and distribution of women’s health solutions. Its products include non-surgical, non-ablative medical device that remodels collagen and restores vaginal tissue. The company was founded on March 3, 1987 and is headquartered Sunnyvale, CA.
